By Raymond Forslund, PhD – Clinical Leader –
The imposition of tariffs by the United States government has introduced significant uncertainties across various industries, including biotechnology. This white paper examines the potential ramifications of these tariffs on biotech manufacturing, funding, and the localization of clinical trials. Additionally, it evaluates whether there is a discernible trend toward conducting more clinical trials in Europe.
A survey conducted by the Biotechnology Innovation Organization (BIO) revealed that nearly 90% of U.S. biotech companies rely on imported components for at least half of their FDA-approved products. The imposition of tariffs on imports from regions such as the European Union (EU), China, and Canada is expected to escalate manufacturing costs.
